Mitchell Shultz, MD
Ophthalmology · Northridge, CANPI 1427153022
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (51.4%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 35 manufacturers reported payments, led by Bausch & Lomb Americas Inc. at 33.0% of the total. Among ophthalmology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 897 payments — averaging $584.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$173K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$150K
- Glaukos Corporation$65K
- Tarsus Pharmaceuticals, Inc.$44K
- Beaver-visitec International, Inc.$23K
- Alcon$15K
- plus $54K from 29 others
Across 117 payments — averaging $5550.51 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bausch Health US, LLC$265K
- Bausch & Lomb Americas Inc.$147K
- Glaukos Corporation$73K
- Beaver-visitec International, Inc.$65K
- Rxsight Inc$44K
- Johnson & Johnson Surgical Vision, Inc.$43K
- plus $12K from 3 others
What the payments were for
- Consulting fees$269,67951%
- Speaking & faculty fees$177,05134%
- Travel & lodging$38,8457%
- Food & beverage$38,7067%
- Gifts$840%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 208 | $173,202 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 190 | $150,178 |
| Glaukos Corporation | 99 | $64,919 |
| Tarsus Pharmaceuticals, Inc. | 52 | $43,858 |
| Beaver-visitec International, Inc. | 1 | $22,960 |
| Alcon | 27 | $15,499 |
| Sight Sciences, Inc. | 24 | $9,226 |
| AbbVie(2 entities) | 81 | $8,389 |
| Ivantis, Inc | 15 | $6,679 |
| Nova Eye, Inc. | 4 | $5,621 |
| NEW World Medical,inc. | 21 | $4,104 |
| Lensar, Inc. | 3 | $3,348 |
| Nordic Pharma, Inc. | 1 | $3,215 |
| Harrow Eye, LLC | 11 | $2,046 |
| Sun Pharmaceutical Industries Inc. | 46 | $2,038 |
| Oyster Point Pharma, Inc. | 25 | $1,900 |
| Carl Zeiss Meditec USA, Inc. | 10 | $1,041 |
| Tearlab Corp | 5 | $1,023 |
| Johnson & Johnson Surgical Vision, Inc. | 10 | $921 |
| Lumenis BE Inc | 2 | $774 |
| Rxsight Inc | 11 | $749 |
| Bausch Health US, LLC | 2 | $718 |
| Ellexiscience | 1 | $395 |
| Carl Zeiss Meditec, Inc. | 4 | $358 |
| Dompe US, Inc. | 6 | $241 |
| Novartis | 10 | $224 |
| Amgen(2 entities) | 9 | $183 |
| Eyepoint US, Inc. | 2 | $144 |
| Eyevance Pharmaceuticals LLC | 2 | $106 |
| Aerie Pharmaceuticals, Inc. | 4 | $86 |
| Omeros Corporation | 3 | $63 |
| Thea Pharma Inc. | 2 | $42 |
| Carl Zeiss Meditec AG | 2 | $39 |
| Kala Pharmaceuticals, Inc. | 2 | $38 |
| Ocular Therapeutix, Inc. | 2 | $37 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- enVista MX60 IOL$76,163
- STELLARIS$55,639
- MIEBO$55,406
- ENVISTA$50,475
- XIIDRA$49,332
- XDEMVY$41,410
- Crystalens Accommodating IOL (AT-52AO)$32,296
- ENVISTA TORIC$27,533
- CRYSTALENS$25,303
- VICTUS$24,020
- TRULIGN TORIC$23,427
- Trulign IOL$21,648
- STELLARIS ELITE$21,612
- iStent inject W$21,065
- enVista Aspire IOL$18,956
- Akreos AO IOL$18,148
- STELLARIS PC$14,801
- AKREOS AO$14,801
- TRYPTYR$13,671
- TENEO$11,603
How this compares
$524,365 in reported general payments places this provider in the 95th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XdemvyLotilaner | 145 | $267,652 |
| XiidraLifitegrast | 217 | $228,080 |
| ProlensaBromfenac Sodium | 320 | $110,331 |
| Lotemax SmLoteprednol Etabonate | 362 | $90,534 |
| RestasisCyclosporine | 92 | $89,192 |
| BesivanceBesifloxacin Hcl | 370 | $81,503 |
| VyzultaLatanoprostene Bunod | 115 | $63,089 |
| MieboPerfluorohexyloctane/Pf | 77 | $59,563 |
| Cyclosporine | 75 | $35,580 |
| LumiganBimatoprost | 53 | $26,754 |
| Bromfenac Sodium | 124 | $25,676 |
| VevyeCyclosporine | 23 | $25,035 |
| Prednisolone Acetate | 525 | $21,495 |
| CombiganBrimonidine Tartrate/Timolol | 47 | $17,109 |
| RocklatanNetarsudil Mesylat/Latanoprost | 22 | $13,961 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta, Miebo | $173,202 | $350,731409 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Lotemax Sm, Besivance, Loteprednol Etabonate | $150,178 | $290,9681,113 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $43,858 | $267,652145 claims |
| AbbVieRestasis, Lumigan, Combigan | $8,389 | $133,055192 claims |
| Harrow Eye, LLCVevye | $2,046 | $25,03523 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $86 | $13,96122 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in Northridge
- Daniel SchwartzSan Francisco$8M
- Michael BerlinWest Hollywood$5.7M
- Gilbert KlimanMenlo Park$1.5M
- Kuldev SinghStanford$1.5M
- Raymond DouglasBeverly Hills$1.3M
- John AffeldtLoma Linda$1.1M
- Srinivas SaddaPasadena$1M
- Sheri RowenNewport Beach$1M
- Savak TeymoorianLaguna Hills$955K
- Andrew MoshfeghiLos Angeles$895K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.